# Takayuki Hamano

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/takayuki-hamano/

## Facts

| Field | Value |
| --- | --- |
| Citations | 10,368 |
| Field | Renal and Vascular Pathologies |
| h-index | 57 |
| i10-index | 151 |
| Last Known Institution | Osaka Gakuin University |
| OpenAlex ID | https://openalex.org/A5000927500 |
| ORCID iD | 0000-0002-2100-9106 |
| Works | 514 |

## Researcher papers

- [Fibroblast Growth Factor-23 and Cardiovascular Events in CKD](https://scholariq.org/papers/fibroblast-growth-factor-23-and-cardiovascular-events-in-ckd/)
- [An Overview of Regular Dialysis Treatment in Japan (As of 31 December 2013)](https://scholariq.org/papers/an-overview-of-regular-dialysis-treatment-in-japan-as-of-31-december-2013/)
- [Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference](https://scholariq.org/papers/dialysis-initiation-modality-choice-access-and-prescription-conclusions-from-a/)
- [Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes](https://scholariq.org/papers/estimated-glomerular-filtration-rate-albuminuria-and-adverse-outcomes/)
- [Fibroblast growth factor 23 is not associated with and does not induce arterial calcification](https://scholariq.org/papers/fibroblast-growth-factor-23-is-not-associated-with-and-does-not-induce-arterial/)
- [Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis](https://scholariq.org/papers/serum-potassium-and-adverse-outcomes-across-the-range-of-kidney-function-a-ckd/)
- [Overview of Regular Dialysis Treatment in Japan (as of 31 December 2008)](https://scholariq.org/papers/overview-of-regular-dialysis-treatment-in-japan-as-of-31-december-2008/)
- [Fetuin-Mineral Complex Reflects Extraosseous Calcification Stress in CKD](https://scholariq.org/papers/fetuin-mineral-complex-reflects-extraosseous-calcification-stress-in-ckd/)
- [Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference](https://scholariq.org/papers/controversies-in-optimal-anemia-management-conclusions-from-a-kidney-disease/)
- [Overview of Regular Dialysis Treatment in <scp>J</scp>apan (as of 31 <scp>D</scp>ecember 2011)](https://scholariq.org/papers/overview-of-regular-dialysis-treatment-in-scp-j-scp-apan-as-of-31-scp-d-scp/)
- [Canagliflozin may increase thromboembolic events in males with erythrocytosis but not in females](https://scholariq.org/papers/canagliflozin-may-increase-thromboembolic-events-in-males-with-erythrocytosis/)
- [Mediators between canagliflozin and renoprotection vary depending on patient characteristics: Insights from the <scp>CREDENCE</scp> trial](https://scholariq.org/papers/mediators-between-canagliflozin-and-renoprotection-vary-depending-on-patient/)

## Researcher topics

- [Renal and Vascular Pathologies](https://scholariq.org/topics/renal-and-vascular-pathologies/)
- [Dialysis and Renal Disease Management](https://scholariq.org/topics/dialysis-and-renal-disease-management/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Parathyroid Disorders and Treatments](https://scholariq.org/topics/parathyroid-disorders-and-treatments/)
- [Pediatric Urology and Nephrology Studies](https://scholariq.org/topics/pediatric-urology-and-nephrology-studies/)

## Researcher university

- [Osaka Gakuin University](https://scholariq.org/institutions/osaka-gakuin-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.